Central Nervous System Stimulants - Economics
Research News and Information

Sunday, November 22, 2009

Second opinions improve ADHD prescribing in a medicaid-insured community population.

29 Jun 2009 OBJECTIVE: The appropriate use of psychotropic medications in youths is an important public health concern. In this article, we describe a review process developed to monitor the use of stimulants and atomoxetine for attention-deficit/hyperactivity ... Read more...

[Drugs for attention deficit hyperactivity disorder]

29 Apr 2009 Quantitative studies have highlighted differences in several drugs approved for use in Spain in the treatment of attention deficit hyperactivity disorder. No clear differences are observed, however, in the case of qualitative studies. The number of ... Read more...

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.

12 Apr 2009 BACKGROUND: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder, affecting 3-6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild stimulant, had long been the only approved medication available ... Read more...

Latest indexed articles for 'Central Nervous System Stimulants - Economics'

These are the very latest articles for this heading:

• Second opinions improve ADHD prescribing in a medicaid-insured community population. 29 Jun 2009
• [Drugs for attention deficit hyperactivity disorder] 29 Apr 2009
• Brain gain: the underground world of neuroenhancing drugs. 25 Apr 2009
• A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. 12 Apr 2009
• Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. 27 Feb 2009
• How to expand the 'sample size' of studies of drug market disruptions. 27 Feb 2009
• Impact of US and Canadian precursor regulation on methamphetamine purity in the United States. 27 Feb 2009
• A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. 29 Apr 2008
• Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. 30 Dec 2007
• [Methylphenidate of retard forms in children and adolescents with ADHD - an overview] 19 Dec 2007
• Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness. 29 Sep 2007
• Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. 30 Aug 2007
• Update on drugs for hyperactivity in childhood. 29 Apr 2007
• Treatment for ADHD: is more complex treatment cost-effective for more complex cases? 30 Jan 2007
• California Substance Abuse Research Consortium, September 2005: update on recent methamphetamine trends in four California regions. 30 Oct 2006
• Essays in public health and preventive medicine. The dangerous betel nut. 27 Feb 2006
• Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment. 30 Dec 2005
• [Better health care for children and adolescents with attention deficit hyperactivity disorder] 8 Dec 2005
• Sociodemographic and economic comparisons of children prescribed longer-acting versus short-acting stimulant medications for attention deficit hyperactivity disorder. 29 Sep 2005
• Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. 30 Aug 2005

See a longer list of these articles.

Technical information about 'Central Nervous System Stimulants'

Definition: A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Registry Number: 0

Descriptor UI: D000697

Alternative terms: Central Nervous System Stimulants; Central Stimulants; Stimulants, Central; Analeptics; Analeptic Drugs; Drugs, Analeptic; Analeptic Agents; Agents, Analeptic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.282; D27.505.954.427.220;

Online Note: use CENTRAL NERVOUS SYSTEM STIMULANTS to search ANALEPTICS 1966-94

History Note: 95; was ANALEPTICS 1963-94; CENTRAL NERVOUS SYSTEM STIMULANTS was see ANALEPTICS 1985-94

Technical Notes: GEN or unspecified; prefer specifics; consider also CENTRAL NERVOUS SYSTEM /drug eff & BRAIN /drug eff; DF: CNS STIMULANTS